Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900301 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TSHRVCAM1APPLMNA | |
| SCHEMBL851413 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TSHRVCAM1APPLMNA | |
| SCHEMBL9107960 | 0.84 | ALDH1A1 (0.40) | ALDH1A1NOTUMLMNAPDE3ATTR | |
| Formaldehyde SCHEMBL28088170 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TSHRVCAM1APPLMNA | |
| SCHEMBL16961340 | 0.82 | NOTUM (0.40) | ALDH1A1NOTUMAPPPDE3AEPHX1 | |
| SCHEMBL16952461 | 0.82 | NOTUM (0.42) | NOTUMAPPPDE3AEPHX1 | |
| SCHEMBL3621190 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TSHRAPPHPGDTTR | |
| SCHEMBL24512644 | 0.79 | SCN9A (0.46) | ALDH1A1TSHRLMNATTRGAA | |
| SCHEMBL31556427 | 0.79 | SCN9A (0.46) | ALDH1A1TSHRLMNATTRGAA | |
| SCHEMBL2094282 | 0.79 | ALDH1A1 (0.47) | ALDH1A1NOTUMTSHRAPPHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108059590-A | A kind of preparation method of 3- trifluoromethoxies -4- chlorobenzaldehydes | 珠海奥博凯生物医药技术有限公司 | 2018-05-22 | — | — | CN | claimed |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| CN-115403584-B | 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| CN-115403584-A | 2-thio-2, 3-dihydropyrimidine-4-one derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001066544-A2 | TRICYCLIC DIHYDROPYRAZOLONE AND TRICYCLIC DIHYDROISOXAZOLONE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-1131322-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1124828-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6274587-B1 | SEXUAL, EATING, CARDIOVASCULAR, BRAIN, NERVOUS SYSTEM, GASTROINTESTINAL AND UROGENITAL DISORDERS | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| WO-2001036422-A1 | TRICYCLIC DIHYDROPYRIMIDINE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-05-25 | — | — | WO | disclosed |
| US-6191140-B1 | POTASSIUM CHANNEL MODULATORS; MUSCLE RELAXANTS; CONTROLLING CELL MEMBRANES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000024743-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024741-A2 | DIHYDROPYRIDINE COMPOUNDS AND THEIR USE AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ALDH1A1 975/4885NOTUM 4486/4885TSHR 1237/4885 |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885NOTUM 3816/4885TSHR 2934/4885 |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | ABCB11, CEL, NDC1 | ALDH1A1 681/4885NOTUM 392/4885TSHR 4461/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885NOTUM 3816/4885TSHR 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.